Vasculitis Clinical Trial
Official title:
A Staged Therapeutic Approach Using Cyclophosphamide and Methotrexate in the Treatment of Wegener's Granulomatosis and Related Vasculitides
This study will evaluate the safety and effectiveness of a staged approach to therapy for
Wegener's granulomatosis and other systemic vasculitides using prednisone plus
cyclophosphamide followed by methotrexate. Vasculitides involve inflammation of blood
vessels (vasculitis) that may affect the brain, nerves, eyes, sinuses, lungs, kidneys,
intestinal tract, skin, joints, heart and other sites. Standard treatment with prednisone
and cyclophosphamide is very effective, but has significant toxicity (adverse side effects).
Methotrexate is also an effective treatment and is less toxic, but it is associated with a
higher rate of disease recurrence and has not been used in patients with severe lung or
kidney disease. Staged therapy using cyclophosphamide first and then methotrexate may
provide better results for overall safety and effectiveness.
Patients 10 to 80 years of age with active Wegener's granulomatosis, polyarteritis nodosa or
a related systemic vasculitis may be eligible for this study. Candidates will be screened
with a medical history and physical examination, blood and urine tests, chest X-ray,
electrocardiogram (EKG) and pulmonary function tests. Other procedures, such as biopsies,
will be done only as medically indicated.
Participants will be treated initially with 1 milligram/kilogram body weight of prednisone
once a day and 2 to 4 mg/kg cyclophosphamide once a day. If the disease improves
significantly, prednisone will be gradually reduced and stopped, and if remission is
achieved, cyclophosphamide will be stopped. Methotrexate will then be started at 0.3 mg/kg
body weight once a week and then increased to 0.5 mg/kg after 2 to 4 weeks. Methotrexate
therapy will continue for at least 2 years. If at the end of 2 years the disease remains in
remission, the methotrexate will be gradually reduced and stopped. If, on the other hand,
active disease recurs during methotrexate treatment, the therapy will be changed. The new
choice of treatment will depend on the severity of recurrence, pre-existing medical
conditions, and previous adverse reactions to prednisone, cyclophosphamide and methotrexate.
Patients will be seen periodically for a physical examination and blood tests to evaluate
disease activity, response to therapy and drug side effects. X-rays will be done as
medically indicated. Evaluations will be scheduled once a month until the patient has been
on methotrexate for 3 months and then every 3 months for the next 18 months. Patients whose
disease remains in remission at that time and are off all medications will be seen every 6
months for another 4 visits.
Status | Completed |
Enrollment | 100 |
Est. completion date | March 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Documentation of WG based on clinical characteristics and histopathological evidence of vasculitis. Patients with a positive C- or P-ANCA and glomerulonephritis as evidence by the presence of red blood cell casts and proteinuria or renal biopsy showing necrotizing glomerulonephritis in the absence of positive immunofluorescence for immunoglobulin and complement will also be eligible. Age 10-80 years. Evidence of active disease as defined by a Vasculitis Disease Activity Index of greater than or equal to 3 or if begun on CTX and glucocorticoid at an outside institution, a history of a Vasculitis Disease Activity Index greater than or equal to 3 at the time of therapy initiation. EXCLUSION CRITERIA: Evidence of active systemic infection which, in the judgement of the investigator, is of greater danger to the patient than the underlying vasculitis. In those instances in which infection cannot be ruled out by gram stain and culture of secretions or collections of fluid in involved organs, it may be necessary to obtain a biopsy of the affected tissue for microbiological and histopathological studies. Patients who are pregnant or who are nursing infants will not be eligible. Fertile women must have a negative pregnancy test within one week prior to study entry and must be using an effective means of birth control. Processes associated with an increased risk of MTX toxicity: acute or chronic liver disease, past history of alcohol abuse (greater than 14 oz. of 100 proof liquor or equivalent per week), ongoing alcohol use of any volume that cannot be discontinued upon entry into the study. Serological evidence of infection with human immunodeficiency virus, hepatitis C, or a positive hepatitis B surface antigen. A serological determination will be performed within two weeks of beginning study participation. Inability to comply with study guidelines. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488-98. — View Citation
Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992 Nov;35(11):1322-9. — View Citation
Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum. 1995 May;38(5):608-13. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02498808 -
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
|
N/A | |
Completed |
NCT01363388 -
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
|
Phase 2 | |
Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT01947465 -
Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
|
N/A | |
Completed |
NCT02240888 -
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
|
N/A | |
Completed |
NCT03693586 -
Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis
|
||
Completed |
NCT05604482 -
CXCR4-PET/CT for Diagnosing Giant Cell Arteritis
|
N/A | |
Completed |
NCT03765424 -
Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT05383339 -
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
|
||
Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
Recruiting |
NCT05565885 -
Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis
|
||
Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
Recruiting |
NCT02856243 -
Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
|
N/A | |
Recruiting |
NCT05628948 -
Vascular Lab Resource (VLR) Biorepository
|
||
Active, not recruiting |
NCT03692416 -
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children
|
Phase 3 | |
Completed |
NCT05115370 -
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
|
||
Terminated |
NCT03937856 -
Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases
|
N/A |